OBJECTIVE: To evaluate the ability of ABLAVAR (Lantheus Medical Imaging), Feraheme (AMAG Pharm), and Prohance (Bracco Diagnostics) to define vascular parameters of ovaries after controlled ovarian stimulation (COS), with possible application to the study of Ovarian Hyperstimulation Syndrome (OHSS).DESIGN: Prohance, a low molecular weight contrast reagent (CR) is used to measure vascular permeability in women and rhesus monkeys, but has limited capabilities to measure blood volume. ABLAVAR which binds to albumin is used to measure the blood pool by MRI, but the vasculature loses protein during OHSS. Feraheme, a nano-sized iron particle, should be a true intravascular CR. Contrast-enhanced MRI and dynamic CE-MRI (DCE-MRI) were performed on macaques during the follicular phase and COS before and after an ovulatory bolus of hCG [Biol Reprod 81(1 Sup):613, 2009]. The ability of ABLAVAR and Feraheme to measure the blood pool was investigated.MATERIALS AND METHODS: Monkeys (n=4) were monitored for menses, and a subset (n=3) subjected to COS as reported [Biol Reprod 71:486-93, 2004]. Oocytes were aspirated 36 h post-hCG. Abdominal images were obtained using the Trio 3T system (Siemens) on the day of hCG (PreA), 3-4 days Post-hCG (PostA), and during the follicular phase (FP) as reported [Proc Int Soc Magn Reson Med 18:6052, 2010] with Prohance and/or Feraheme or ABLAVAR.RESULTS: Prohance identified extravascular areas associated with antral and non-luteinized follicles and corpora lutea both PreA and PostA. ABLAVAR showed minimal leakage of this CR during the FP and PreA. Systemic leakage of ABLAVAR was observed PostA and associated with abdominal fluid. Feraheme signal was limited to the blood pool both PreA and PostA.CONCLUSION: Prohance and ABLAVAR offer complementary data on vascular parameters of COS ovaries, with ABLAVAR indicating possible protein leakage from the vasculature during OHSS symptoms PostA. Feraheme appears to be a true intravascular agent in MRI scanning during COS. OBJECTIVE: To evaluate the ability of ABLAVAR (Lantheus Medical Imaging), Feraheme (AMAG Pharm), and Prohance (Bracco Diagnostics) to define vascular parameters of ovaries after controlled ovarian stimulation (COS), with possible application to the study of Ovarian Hyperstimulation Syndrome (OHSS). DESIGN: Prohance, a low molecular weight contrast reagent (CR) is used to measure vascular permeability in women and rhesus monkeys, but has limited capabilities to measure blood volume. ABLAVAR which binds to albumin is used to measure the blood pool by MRI, but the vasculature loses protein during OHSS. Feraheme, a nano-sized iron particle, should be a true intravascular CR. Contrast-enhanced MRI and dynamic CE-MRI (DCE-MRI) were performed on macaques during the follicular phase and COS before and after an ovulatory bolus of hCG [Biol Reprod 81(1 Sup):613, 2009]. The ability of ABLAVAR and Feraheme to measure the blood pool was investigated. MATERIALS AND METHODS: Monkeys (n=4) were monitored for menses, and a subset (n=3) subjected to COS as reported [Biol Reprod 71:486-93, 2004]. Oocytes were aspirated 36 h post-hCG. Abdominal images were obtained using the Trio 3T system (Siemens) on the day of hCG (PreA), 3-4 days Post-hCG (PostA), and during the follicular phase (FP) as reported [Proc Int Soc Magn Reson Med 18:6052, 2010] with Prohance and/or Feraheme or ABLAVAR. RESULTS: Prohance identified extravascular areas associated with antral and non-luteinized follicles and corpora lutea both PreA and PostA. ABLAVAR showed minimal leakage of this CR during the FP and PreA. Systemic leakage of ABLAVAR was observed PostA and associated with abdominal fluid. Feraheme signal was limited to the blood pool both PreA and PostA. CONCLUSION: Prohance and ABLAVAR offer complementary data on vascular parameters of COS ovaries, with ABLAVAR indicating possible protein leakage from the vasculature during OHSS symptoms PostA. Feraheme appears to be a true intravascular agent in MRI scanning during COS.
Read full abstract